Abstract: The present disclosure provides a truncated Evans Blue modified fibroblast activation protein inhibitor compound. The compound is formed by connecting truncated Evans Blue, a fibroblast activation protein inhibitor and a nuclide chelating group by means of connecting groups L1, L2, L3, L4 and X. The compound has the following structure shown in Formula (I), where R1 is a fibroblast activation protein inhibitor; L1 is lysine, glutamic acid, or a derivative structure thereof; L2 is —(CH2)n—, n is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; L3 is —(CH2)m—, m is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O— or —(CO)—; L4 is —(CH2)p—, p is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; X is selected from N, C, O, S, or and R2 is a nuclide chelating group.

Abstract: The present disclosure provides a compound targeting prostate specific membrane antigen (PSMA), wherein the compound has the following structure shown in Formula (I); R1 is a compound structure targeting prostate specific membrane antigen; L1 is -(X)n-(CH2)m-(Y)q-, X and Y are independently selected from lysine, glutamic acid or a derivative structure containing lysine and glutamic acid, n is an integer from 0 to 12, m is an integer from 0 to 60, q is an integer from 0 to 12, and each CH2 may be individually substituted with —O—, —NH(CO)—, or —(CO)—NH—; L2 is -(CH2)p-, p is an integer from 0 to 30, and each CH2 may be individually substituted with —O—, —NH(CO)—, or —(CO)—NH—; and R2 is a nuclide chelating group. The present disclosure also provides a radiolabeled complex based on the structure of the compound.